Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Awakn Life Sciences Corp (OP:AWKNF)

0.0650 UNCHANGED
Last Price Updated: 3:11 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Awakn Life Sciences Corp

< Previous 1 2 3 4 5 Next >
News headline image
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More ↗
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... 
Via Benzinga
News headline image
MDMA News: Exclusive Supply Deal With Awakn Life Sciences & Canadian Company Expands Psychedelics Production ↗
PharmAla To Be Exclusive MDMA Supply Partner To Awakn Life Sciences Effective immediately, MDXX class molecules producer PharmAla Biotech Holdings Inc. will become the exclusive MDMA supplier to Awakn... 
Via Benzinga
News headline image
Latest Psychedelics Deals: Optimi Supplies Australia, Awakn Partners Licensing In California ↗
Optimi Health Enters Australian Medical Psychedelics Market Via Mind Medicine Australia 
Via Benzinga
News headline image
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More ↗
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and... 
Via Benzinga
News headline image
Awakn's First Licensing Partnership Deal In Europe Involves Chain Of Portuguese Clinics ↗
Awakn Life Sciences Corp. (OTCQB: AWKNF) has signed a licensing partnership agreement in Europe with a Portugal-based healthcare consortium currently operating in stealth mode.   
Via Benzinga
News headline image
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More ↗
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and... 
Via Benzinga
News headline image
Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program ↗
Awakn Opens Fourth European Clinic, Norway Takes Center Stage 
Via Benzinga
News headline image
Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More ↗
Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More 
Via Benzinga
News headline image
A New Way Of Delivering MDMA? Awakn And Tech Partner Are Set To Study Viability ↗
Psychedelics biotech Awakn Life Sciences (OTCQB: AWKNF) has initiated a feasibility study of formulating and delivering MDMA through Catalent’s proprietary oral, 
Via Benzinga
Awakn Life Sciences Corp Shares Rally 77% After Earning ILAP Expedited Approval Pathway For Its Ketamine-Assisted AUD Therapeutic ($AWKNF)
Via AB Newswire
News headline image
Awakn's Ketamine Treatment For Alcohol Use Disorder Awarded UK's Fast-Track Status ↗
Awakn Life Sciences Corp. (OTCQB: AWKNF), a biotech company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), has been granted an Innovation Passport for... 
Via Benzinga
Awakn Life Sciences Corp Earns Global AUD Treatment Interest With A New Class Of Psychedelics-Based Therapeutic ($AWKNF)
Via AB Newswire
News headline image
Two New Studies On Classical Psychedelics: Grading Ketamine's Components, Tuning Down Psilocybin Dosing ↗
Awakn’s First Study On Novel S-Ketamine Formulation To Assess Dissociative Effect 
Via Benzinga
News headline image
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways ↗
What a year for psychedelics! 
Via Benzinga
News headline image
6 Largest Psychedelic Drug Stocks Were -20% In December ↗
The Psychedelic Drug Stocks Index, which tracks the six largest psychedelic stocks researching the treatment of mental illnesses based on the use of one or more psychedelic substances, continued to... 
Via Talk Markets
News headline image
Largest Psychedelic Stocks DOWN 8% Last Week; DOWN 22% So Far This Month ↗
Today's article highlights the performance of the munKNEE Psychedelic Drug Stocks Index which tracks the six (6) largest psychedelic stocks researching the treatment of mental illnesses based on the... 
Via Talk Markets
News headline image
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More ↗
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. 
Via Benzinga
News headline image
Awakn Unveils Q3 Results, Touts Revenue Growth, R&D Progress, Commercial Plans ↗
Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) shared its financial results and business highlights for a three-month period that ended Oct. 31, 2022. Financials showed: 
Via Benzinga
News headline image
UK Supports Psychedelic Research With Phase 3 Trial In Federal Health Sites ↗
Awakn Life Sciences Corp. 
Via Benzinga
News headline image
Major Psychedelic Drug Stocks DOWN 9% Last Week; Now Down 51% YTD ↗
Today's article highlights the performance of the largest psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of ten (10) different psychedelic substances. 
Via Talk Markets
News headline image
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project ↗
Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and... 
Via Benzinga
News headline image
Europe To Have Expanded Access To Psychedelic-Assisted Therapy With New Norway Clinic ↗
Psychedelics biotech Awakn Life Sciences Corp. 
Via Benzinga
News headline image
Psyched: Full-Dose & Microdosing LSD Studies, Research Scope For Fed Funding, Consumption Sites And More ↗
LSD Research Ramps Up: Full-Dose & Microdosing For Alzheimer's Studies Led By Beckley Foundation Coming Soon 
Via Benzinga
News headline image
Psychedelic Drug Stocks Index Has A Good Week ↗
We track six psychedelic stocks researching the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances. 
Via Talk Markets
News headline image
A Leading Ketamine Treatment Clinic For Alcoholism Is Expanding: Here's The Latest ↗
A psychedelics R&D biotech company, known for providing novel treatments for addictions, is opening a new ketamine clinic.  
Via Benzinga
News headline image
Psychedelic Drug Stocks Index Continued To Decline Last Week ↗
This article highlights the performances of the 6 constituents in the munKNEE Psychedelic Drug Stocks Index last week and in the last 3 weeks and the extent to which each company is likely to encounter... 
Via Talk Markets
News headline image
Psyched: Colorado Legalizes Psychedelics, NYC Treats Alcoholism With Ketamine, $30M Series A For Startup ↗
Colorado Voters Approve Initiative To Legalize And Regulate Psychedelics 
Via Benzinga
News headline image
EXCLUSIVE: New Partnership Brings Leading Psychedelic Protocol For Alcoholism Treatment To NYC ↗
NYC-based clinics brand Nushama has partnered with Awakn Life Sciences (OTCQB: AWKNF), a clinical-stage psychedelics biotech company to bring 
Via Benzinga
News headline image
Can Ketamine Treat Alcohol Addiction? In-Clinic Therapy Vs. Retreats ↗
(Part four of a four-part series - Read part three) 
Via Benzinga
News headline image
Can Ketamine Treat Alcohol Addiction? The Awakn Approach ↗
(Part three of a four-part series) 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.